Pharmacokinetic and Pharmacodynamic Aspects of Antibiotic Use in High-Risk Populations

Infectious Disease Clinics of North America

Volumn 21, Issue 3, 2007, Pages 821-846

  Bergman, Scott J ^a,b   Speil, Cristian ^b   Short, Michael ^c   Koirala, Janak ^b  

^a SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEMORIAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DICLOXACILLIN; DOXYCYCLINE; ERTAPENEM; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; MOXIFLOXACIN; NAFCILLIN; OXACILLIN; RIFAMPICIN; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

AGING; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BURN; CHRONIC LUNG DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; ERADICATION THERAPY; HIGH RISK POPULATION; HUMAN; INFECTION RISK; KIDNEY FAILURE; LIVER FAILURE; LOADING DRUG DOSE; NEPHROTOXICITY; NONHUMAN; OBESITY; OTOTOXICITY; PROSTHESIS; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; HUMANS; INFECTION; RISK FACTORS;

EID: 34548449840     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2007.07.004     Document Type: Review

References (146)

1. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 1 (1998) 1-10
2. Tsuji A. Impact of transporter-mediated drug absorption, distribution, elimination and drug interactions in antimicrobial chemotherapy. J Infect Chemother 12 5 (2006) 241-250
3. Peterson L.R., and Gerding D.N. Influence of protein binding of antibiotics on serum pharmacokinetics and extravascular penetration: clinically useful concepts. Rev Infect Dis 2 3 (1980) 340-348
4. Craig W.A., and Ebert S.C. Protein binding and its significance in antibacterial therapy. Infect Dis Clin North Am 3 3 (1989) 407-414
5. Mandell GL, Douglas RG, Bennett JE, et al. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. [cover art] 6th:2 v. (xxxviii, 3661, cxxx p.). Available at: http://firstsearch.oclc.org/WebZ/DCARead?standardNoType=1&;standardNo=0443066434:srcdbname=worldcat:fromExternal=true&sessionid=0. Accessed April 30, 2006.
6. Levison M.E. Pharmacodynamics of antimicrobial drugs. Infect Dis Clin North Am 18 3 (2004) 451-465 vii
7. Moise-Broder P.A., Forrest A., Birmingham M.C., et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 43 13 (2004) 925-942
8. Maglio D., Nightingale C.H., and Nicolau D.P. Extended interval aminoglycoside dosing: from concept to clinic. Int J Antimicrob Agents 19 (2002) 341-348
9. Schentag J.J., Gilliland K.K., and Paladino J.A. What have we learned from pharmacokinetic and pharmacodynamic theories?. Clin Infect Dis 32 Suppl 1 (2001) S39-S46
10. Ambrose P.G., Bhavnani S.M., and Owens Jr. R.C. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am 17 3 (2003) 529-543
11. Maglio D., Nicolau D.P., and Nightingale C.H. Impact of pharmacodynamics on dosing of macrolides, azalides, and ketolides. Infect Dis Clin North Am 17 3 (2003) 563-577 vi
12. Craig W.A. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 17 3 (2003) 479-501
13. Bustamante C.I., Drusano G.L., Tatem B.A., et al. Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob Agents Chemother 26 5 (1984) 678-682
14. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 39 3 (2000) 215-231
15. Bearden D.T., and Rodvold K.A. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin Pharmacokinet 38 5 (2000) 415-426
16. Morgan D.J., and Bray K.M. Lean body mass as a predictor of drug dosage: implications for drug therapy. Clin Pharmacokinet 26 4 (1994) 292-307
17. Marangos M.N., Skoutelis A.T., Nightingale C.H., et al. Absorption of ciprofloxacin in patients with diabetic gastroparesis. Antimicrob Agents Chemother 39 9 (1995) 2161-2163
18. Salazar D.E., and Corcoran G.B. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 84 6 (1988) 1053-1060
19. Snider R.D., Kruse J.A., Bander J.J., et al. Accuracy of estimated creatinine clearance in obese patients with stable renal function in the intensive care unit. Pharmacotherapy 15 6 (1995) 747-753
20. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 1 (1976) 31-41
21. Bauer L.A., Black D.J., and Lill J.S. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 54 8 (1998) 621-625
22. Penzak S.R., Gubbins P.O., Rodvold K.A., et al. Therapeutic drug monitoring of vancomycin in a morbidly obese patient. Ther Drug Monit 20 3 (1998) 261-265
23. Dvorchik B.H., and Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol 45 1 (2005) 48-56
24. Pai M.P., Mercier R.C., and Allen S.E. Using vancomycin concentrations for dosing daptomycin in a morbidly obese patient with renal insufficiency. Ann Pharmacother 40 3 (2006) 553-558
25. Stein G.E., Schooley S.L., Peloquin C.A., et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 39 3 (2005) 427-432
26. Davis RL, Quenzer RW, Weller S, et al. Acyclovir pharmacokinetics in morbid obesity [abstract 765]. Paper presented at the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 29-October 2, 1991.
27. Christiansen K.J., Bernard E.M., Gold J.W., et al. Distribution and activity of amphotericin B in humans. J Infect Dis 152 5 (1985) 1037-1043
28. Collette N., Van der Auwera P., Meunier F., et al. Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. J Antimicrob Chemother 27 4 (1991) 535-548
29. Gillum J.G., Johnson M., Lavoie S., et al. Flucytosine dosing in an obese patient with extrameningeal cryptococcal infection. Pharmacotherapy 15 2 (1995) 251-253
30. Cohen L.G., DiBiasio A., Lisco S.J., et al. Fluconazole serum concentrations and pharmacokinetics in an obese patient. Pharmacotherapy 17 5 (1997) 1023-1026
31. Rex J.H., Bennett J.E., Sugar A.M., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 331 20 (1994) 1325-1330
32. Allard S., Kinzig M., Boivin G., et al. Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther 54 4 (1993) 368-373
33. Yuk J., Nightingale C.H., Sweeney K., et al. Pharmacokinetics of nafcillin in obesity. J Infect Dis 157 5 (1988) 1088-1089
34. Geiseler P.J., Manis Jr. R.D., and Maddux M.S. Dosage of antituberculous drugs in obese patients. Am Rev Respir Dis 131 6 (1985) 944-946
35. Chen M., Nafziger A.N., Drusano G.L., et al. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother 50 4 (2006) 1222-1227
36. Tilstone W.J., and Fine A. Furosemide kinetics in renal failure. Clin Pharmacol Ther 23 6 (1978) 644-650
37. Kays M.B., Overholser B.R., Mueller B.A., et al. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis 42 6 (2003) 1253-1259
38. Livornese Jr. L.L., Slavin D., Gilbert B., et al. Use of antibacterial agents in renal failure. Infect Dis Clin North Am 18 3 (2004) 551-579 viii-ix
39. Nolin T.D., Frye R.F., and Matzke G.R. Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis 42 5 (2003) 906-925
40. Nolin T.D., Appiah K., Kendrick S.A., et al. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol 17 9 (2006) 2363-2367
41. Barth R.H., and DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int 50 3 (1996) 929-936
42. Ariano R.E., Fine A., Sitar D.S., et al. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis. Am J Kidney Dis 46 4 (2005) 681-687
43. Stamatakis M.K., Schreiber J.M., Slain D., et al. Vancomycin administration during dialysis with low-flux polysulfone membranes: traditional versus a supplemental dosage regimen. Am J Health Syst Pharm 60 15 (2003) 1564-1568
44. Bergman SJ, Slain D, Hare J. Evaluation of thrice weekly vancomycin dosing in high-flux hemodialysis [abstract 373]. Presented at the American College of Clinical Pharmacy Annual Meeting. St Louis, October 26-29, 2006.
45. Foote E.F., Dreitlein W.B., Steward C.A., et al. Pharmacokinetics of vancomycin when administered during high flux hemodialysis. Clin Nephrol 50 1 (1998) 51-55
46. Pechere J.C., and Dugal R. Pharmacokinetics of intravenously administered tobramycin in normal volunteers and in renal-impaired and hemodialyzed patients. J Infect Dis 134 Suppl (1976) S118-S124
47. Westphal J.F., and Brogard J.M. Clinical pharmacokinetics of newer antibacterial agents in liver-disease. Clin Pharmacokinet 24 1 (1993) 46-58
48. Lanao J.M., Dominguez-Gil A., Macias J.G., et al. The influence of ascites on the pharmacokinetics of amikacin. Int J Clin Pharmacol Ther Toxicol 18 2 (1980) 57-61
49. Garcia M.J., Dominguez-Gil A., Perez F.D., et al. Disposition of cefoxitin in patients with ascites. Eur J Clin Pharmacol 20 5 (1981) 371-374
50. Bergan T., Engeset A., and Olszewski W. Does serum protein binding inhibit tissue penetration of antibiotics?. Rev Infect Dis 9 4 (1987) 713-718
51. Reidenberg M.M., and Breckenridge A. Drugs and the liver. Clin Pharmacol Ther 64 4 (1998) 353-354
52. Tschida S.J., Vance-Bryan K., and Zaske D.E. Anti-infective agents and hepatic disease. Med Clin North Am 79 4 (1995) 895-917
53. Stoeckel K., and Koup J.R. Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model. Am J Med 77 4C (1984) 26-32
54. Stoeckel K., Tuerk H., Trueb V., et al. Single-dose ceftriaxone kinetics in liver insufficiency. Clin Pharmacol Ther 36 4 (1984) 500-509
55. Frost R.W., Lettieri J.T., Krol G., et al. The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin. Clin Pharmacol Ther 45 6 (1989) 608-616
56. Dixit R.K., Satapathy S.K., Kumar R., et al. Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis. Indian J Gastroenterol 21 2 (2002) 62-63
57. Esposito S., Miniero M., Barba D., et al. Pharmacokinetics of ciprofloxacin in impaired liver function. Int J Clin Pharmacol Res 9 1 (1989) 37-41
58. Ruhnke M., Trautmann M., Borner K., et al. Pharmacokinetics of ciprofloxacin in liver cirrhosis. Chemotherapy 36 6 (1990) 385-391
59. Fish D.N., and Chow A.T. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 32 2 (1997) 101-119
60. North D.S., Fish D.N., and Redington J.J. Levofloxacin, a second-generation fluoroquinolone. Pharmacotherapy 18 5 (1998) 915-935
61. Avant G.R., Schenker S., and Alford R.H. The effect of cirrhosis on the disposition and elimination of clindamycin. Am J Dig Dis 20 3 (1975) 223-230
62. Eng R.H., Gorski S., Person A., et al. Clindamycin elimination in patients with liver disease. J Antimicrob Chemother 8 4 (1981) 277-281
63. Williams D.N., Crossley K., Hoffman C., et al. Parenteral clindamycin phosphate: pharmacology with normal and abnormal liver function and effect on nasal staphylococci. Antimicrob Agents Chemother 7 2 (1975) 153-158
64. Lamp K.C., Freeman C.D., Klutman N.E., et al. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 36 5 (1999) 353-373
65. Lau A.H., Evans R., Chang C.W., et al. Pharmacokinetics of metronidazole in patients with alcoholic liver disease. Antimicrob Agents Chemother 31 11 (1987) 1662-1664
66. Loft S., Sonne J., Dossing M., et al. Metronidazole pharmacokinetics in patients with hepatic encephalopathy. Scand J Gastroenterol 22 1 (1987) 117-123
67. Barre J., Mallat A., Rosenbaum J., et al. Pharmacokinetics of erythromycin in patients with severe cirrhosis: respective influence of decreased serum binding and impaired liver metabolic capacity. Br J Clin Pharmacol 23 6 (1987) 753-757
68. Hall K.W., Nightingale C.H., Gibaldi M., et al. Pharmacokinetics of erythromycin in normal and alcoholic liver disease subjects. J Clin Pharmacol 22 7 (1982) 321-325
69. Rodvold K.A. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 37 5 (1999) 385-398
70. Chu S.Y., Granneman G.R., Pichotta P.J., et al. Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics. J Clin Pharmacol 33 5 (1993) 480-485
71. Ballow C.H., and Amsden G.W. Azithromycin: the first azalide antibiotic. Ann Pharmacother 26 10 (1992) 1253-1261
72. Rapp R.P. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactions. Ann Pharmacother 32 7-8 (1998) 785-793
73. Schentag J.J., and Ballow C.H. Tissue-directed pharmacokinetics. Am J Med 91 3A (1991) 5S-11S
74. Mazzei T., Surrenti C., Novelli A., et al. Pharmacokinetics of azithromycin in patients with impaired hepatic function. J Antimicrob Chemother 31 Suppl E (1993) 57-63
75. Moore R.D., Smith C.R., and Lietman P.S. Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides. Am J Med 80 6 (1986) 1093-1097
76. Moore R.D., Smith C.R., Lipsky J.J., et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 100 3 (1984) 352-357
77. Lietman P.S. Liver disease, aminoglycoside antibiotics and renal dysfunction. Hepatology 8 4 (1988) 966-968
78. Contreras A.M., Ramirez M., Cueva L., et al. Low serum albumin and the increased risk of amikacin nephrotoxicity. Rev Invest Clin 46 1 (1994) 37-43
79. Gamba G., Contreras A.M., Cortes J., et al. Hypoalbuminemia as a risk factor for amikacin nephrotoxicity. Rev Invest Clin 42 3 (1990) 204-209
80. Cortes J., Gamba G., Contreras A., et al. Amikacin nephrotoxicity in patients with chronic liver disease. Rev Invest Clin 42 2 (1990) 93-98
81. Kopanoff D.E., Snider Jr. D.E., and Caras G.J. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 117 6 (1978) 991-1001
82. Fernandez-Villar A., Sopena B., Vazquez R., et al. Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis 36 3 (2003) 293-298
83. Acocella G., Bonollo L., Garimoldi M., et al. Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease. Gut 13 1 (1972) 47-53
84. Van Gossum A., Quenon M., Van Gossum M., et al. Penetration of cefoperazone into ascites. Eur J Clin Pharmacol 37 6 (1989) 577-580
85. Montay G., and Gaillot J. Pharmacokinetics of fluoroquinolones in hepatic failure. J Antimicrob Chemother 26 Suppl B (1990) 61-67
86. Terg R., Cobas S., Fassio E., et al. Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study. J Hepatol 33 4 (2000) 564-569
87. Scheetz M.H., Reddy P., Nicolau D.P., et al. Peritoneal fluid penetration of tigecycline. Ann Pharmacother 40 11 (2006) 2064-2067
88. Pea F., Viale P., and Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 44 10 (2005) 1009-1034
89. Boselli E., Breilh D., Rimmele T., et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 33 7 (2005) 1529-1533
90. Cruciani M., Gatti G., Lazzarini L., et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 38 5 (1996) 865-869
91. Silverman J.A., Mortin L.I., Vanpraagh A.D., et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191 12 (2005) 2149-2152
92. Drusano G.L. Infection site concentrations: their therapeutic importance and the macrolide and macrolide-like class of antibiotics. Pharmacotherapy 25 12 Pt 2 (2005) 150S-158S
93. Touw D.J. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis. Pharm World Sci 20 4 (1998) 149-160
94. Beringer P., Huynh K.M., Kriengkauykiat J., et al. Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. Antimicrob Agents Chemother 49 12 (2005) 5013-5017
95. Rey E., Treluyer J.M., and Pons G. Drug disposition in cystic fibrosis. Clin Pharmacokinet 35 4 (1998) 313-329
96. Touw D.J., Vinks A.A., Mouton J.W., et al. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis: current practice and suggestions for future directions. Clin Pharmacokinet 35 6 (1998) 437-459
97. Smith A.L., Fiel S.B., Mayer-Hamblett N., et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 123 5 (2003) 1495-1502
98. Smyth A., Tan K.H., Hyman-Taylor P., et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial. Lancet 365 9459 (2005) 573-578
99. Burkhardt O., Lehmann C., Madabushi R., et al. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?. J Antimicrob Chemother 58 4 (2006) 822-829
100. Bergman SJ, Slain D, Petros K. Evaluation of a newly implemented once-daily aminoglycoside dosing and monitoring program [abstract 434]. Paper presented at the American Society of Health-System Pharmacists Midyear Clinical Meeting. Anaheim, December 3-7, 2006.
101. Lee C.K., Boyle M.P., Diener-West M., et al. Levofloxacin pharmacokinetics in adult cystic fibrosis. Chest 131 3 (2007) 796-802
102. Pleasants R.A., Michalets E.L., Williams D.M., et al. Pharmacokinetics of vancomycin in adult cystic fibrosis patients. Antimicrob Agents Chemother 40 1 (1996) 186-190
103. Saralaya D., Peckham D.G., Hulme B., et al. Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis. J Antimicrob Chemother 53 2 (2004) 325-328
104. Weinbren M.J. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother 44 3 (1999) 319-327
105. Moore R.D., Smith C.R., and Lietman P.S. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 149 3 (1984) 443-448
106. Zaske D.E., Sawchuk R.J., Gerding D.N., et al. Increased dosage requirements of gentamicin in burn patients. J Trauma 16 10 (1976) 824-828
107. Hollingsed T.C., Harper D.J., Jennings J.P., et al. Aminoglycoside dosing in burn patients using first-dose pharmacokinetics. J Trauma 35 3 (1993) 394-398
108. Zaske D.E., Chin T., Kohls P.R., et al. Initial dosage regimens of gentamicin in patients with burns. J Burn Care Rehabil 12 1 (1991) 46-50
109. Rybak M.J., Albrecht L.M., Berman J.R., et al. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 34 5 (1990) 792-795
110. Rice T.L. Simplified dosing and monitoring of vancomycin for the burn care clinician. Burns 18 5 (1992) 355-361
111. Boucher B.A., Kuhl D.A., and Hickerson W.L. Pharmacokinetics of systemically administered antibiotics in patients with thermal injury. Clin Infect Dis 14 2 (1992) 458-463
112. McKinnon P.S., and Davis S.L. Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases. Eur J Clin Microbiol Infect Dis 23 4 (2004) 271-288
113. Kiser T.H., Hoody D.W., Obritsch M.D., et al. Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. Antimicrob Agents Chemother 50 6 (2006) 1937-1945
114. Gristina A.G. Biomaterial-centered infection: microbial adhesion versus tissue integration. Science 237 4822 (1987) 1588-1595
115. Blaser J., Vergeres P., Widmer A.F., et al. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob Agents Chemother 39 5 (1995) 1134-1139
116. Mack D., Rohde H., Harris L.G., et al. Biofilm formation in medical device-related infection. Int J Artif Organs 29 4 (2006) 343-359
117. Gristina A.G., and Costerton J.W. Bacterial adherence to biomaterials and tissue: the significance of its role in clinical sepsis. J Bone Joint Surg Am 67 2 (1985) 264-273
118. Khardori N., and Yassien M. Biofilms in device-related infections. J Ind Microbiol 15 3 (1995) 141-147
119. Donlan R.M. Biofilm formation: a clinically relevant microbiological process. Clin Infect Dis 33 8 (2001) 1387-1392
120. Vergeres P., and Blaser J. Amikacin, ceftazidime, and flucloxacillin against suspended and adherent Pseudomonas aeruginosa and Staphylococcus epidermidis in an in vitro model of infection. J Infect Dis 165 2 (1992) 281-289
121. Widmer A.F., Frei R., Rajacic Z., et al. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis 162 1 (1990) 96-102
122. Widmer A.F., Wiestner A., Frei R., et al. Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections. Antimicrob Agents Chemother 35 4 (1991) 741-746
123. Stewart P.S., and Costerton J.W. Antibiotic resistance of bacteria in biofilms. Lancet 358 9276 (2001) 135-138
124. Stewart P.S. Theoretical aspects of antibiotic diffusion into microbial biofilms. Antimicrob Agents Chemother 40 11 (1996) 2517-2522
125. Anderl J.N., Franklin M.J., and Stewart P.S. Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother 44 7 (2000) 1818-1824
126. Mah T.F., and O'Toole G.A. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 9 1 (2001) 34-39
127. Brown M.R., Allison D.G., and Gilbert P. Resistance of bacterial biofilms to antibiotics: a growth-rate related effect?. J Antimicrob Chemother 22 6 (1988) 777-780
128. Gilbert P., Das J., and Foley I. Biofilm susceptibility to antimicrobials. Adv Dent Res 11 1 (1997) 160-167
129. Ashby M.J., Neale J.E., Knott S.J., et al. Effect of antibiotics on non-growing planktonic cells and biofilms of Escherichia coli. J Antimicrob Chemother 33 3 (1994) 443-452
130. Drinkovic D., Morris A.J., Pottumarthy S., et al. Bacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis. J Antimicrob Chemother 52 5 (2003) 820-825
131. Chamovitz B., Bryant R.E., Gilbert D.N., et al. Prosthetic valve endocarditis caused by Staphylococcus epidermidis. Development of rifampin resistance during vancomycin and rifampin therapy. JAMA 253 19 (1985) 2867-2868
132. Gagnon R.F., Richards G.K., and Kostiner G.B. Time-kill efficacy of antibiotics in combination with rifampin against Staphylococcus epidermidis biofilms. Adv Perit Dial 10 (1994) 189-192
133. Richards G.K., Morcos R.J., and Gagnon R.F. The differential activity of aminoglycoside antibiotics with rifampin explored in a kinetic in vitro model of implant-associated infection (Staphylococcus epidermidis). Adv Perit Dial 10 (1994) 183-188
134. Gagnon R.F., Richards G.K., and Wiesenfeld L. Staphylococcus epidermidis biofilms: unexpected outcome of double and triple antibiotic combinations with rifampin. ASAIO Trans 37 3 (1991) M158-M160
135. Wilson W.R., Karchmer A.W., Dajani A.S., et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. JAMA 274 21 (1995) 1706-1713
136. Le T., and Bayer A.S. Combination antibiotic therapy for infective endocarditis. Clin Infect Dis 36 5 (2003) 615-621
137. Chang F.Y. Staphylococcus aureus bacteremia and endocarditis. J Microbiol Immunol Infect 33 2 (2000) 63-68
138. McCue J.D. Antibiotic use in the elderly: issues and nonissues. Clin Infect Dis 28 4 (1999) 750-752
139. Faulkner C.M., Cox H.L., and Williamson J.C. Unique aspects of antimicrobial use in older adults. Clin Infect Dis 40 7 (2005) 997-1004
140. Swift C.G. Pharmacokinetics and prescribing in the elderly. J Antimicrob Chemother 34 Suppl A (1994) 25-32
141. Drusano G.L., Munice Jr. H.L., Hoopes J.M., et al. Commonly used methods of estimating creatinine clearance are inadequate for elderly debilitated nursing home patients. J Am Geriatr Soc 36 5 (1988) 437-441
142. O'Connell M.B., Dwinell A.M., and Bannick-Mohrland S.D. Predictive performance of equations to estimate creatinine clearance in hospitalized elderly patients. Ann Pharmacother 26 5 (1992) 627-635
143. Stalam M., and Kaye D. Antibiotic agents in the elderly. Infect Dis Clin North Am 18 3 (2004) 533-549 viii
144. DiPiro J.T. Pharmacotherapy: a pathophysiologic approach. 6th edition (2005), McGraw-Hill, London(UK)
145. Drusano G.L., Preston S.L., Fowler C., et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 189 9 (2004) 1590-1597
146. Shorr A.F., Zadeikis N., Xiang J.X., et al. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia. Clin Ther 27 8 (2005) 1251-1259